A phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma

J. M. Kirkwood; P. Lorigan; P. Hersey; A. Hauschild; C. Robert; D. F. McDermott; J. Gomez-Navarro; J. Q. Liang; C. A. Bulanhagui

Journal Article

A phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma

Kirkwood J
Lorigan P
Hersey P
et al.

Journal of Clinical Oncology (2008) 26(15_suppl) 9023-9023

DOI: 10.1200/jco.2008.26.15_suppl.9023

N/ACitations

N/AReaders

Get full text

Cite

CITATION STYLE

APA

Kirkwood, J. M., Lorigan, P., Hersey, P., Hauschild, A., Robert, C., McDermott, D. F., … Bulanhagui, C. A. (2008). A phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Journal of Clinical Oncology, 26(15_suppl), 9023–9023. https://doi.org/10.1200/jco.2008.26.15_suppl.9023

A phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma

Cite

Register to see more suggestions